KR101832041B1 - 국소 스테로이드 조성물 및 방법 - Google Patents

국소 스테로이드 조성물 및 방법 Download PDF

Info

Publication number
KR101832041B1
KR101832041B1 KR1020157012541A KR20157012541A KR101832041B1 KR 101832041 B1 KR101832041 B1 KR 101832041B1 KR 1020157012541 A KR1020157012541 A KR 1020157012541A KR 20157012541 A KR20157012541 A KR 20157012541A KR 101832041 B1 KR101832041 B1 KR 101832041B1
Authority
KR
South Korea
Prior art keywords
alcohol
topical lotion
fatty alcohol
weight
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157012541A
Other languages
English (en)
Korean (ko)
Other versions
KR20150069005A (ko
Inventor
에이. 존슨 키스
에프. 포프 칼
Original Assignee
미칼 파마슈티컬스 엘엘씨 - 에이치 시리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50485547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101832041(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미칼 파마슈티컬스 엘엘씨 - 에이치 시리즈 filed Critical 미칼 파마슈티컬스 엘엘씨 - 에이치 시리즈
Publication of KR20150069005A publication Critical patent/KR20150069005A/ko
Application granted granted Critical
Publication of KR101832041B1 publication Critical patent/KR101832041B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157012541A 2012-10-18 2013-10-16 국소 스테로이드 조성물 및 방법 Expired - Fee Related KR101832041B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261715467P 2012-10-18 2012-10-18
US61/715,467 2012-10-18
US13/921,833 2013-06-19
US13/921,859 US20140112959A1 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
US13/921,859 2013-06-19
US13/921,833 US8962028B2 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
PCT/US2013/065266 WO2014062817A1 (en) 2012-10-18 2013-10-16 Topical steroid composition and method

Publications (2)

Publication Number Publication Date
KR20150069005A KR20150069005A (ko) 2015-06-22
KR101832041B1 true KR101832041B1 (ko) 2018-02-23

Family

ID=50485547

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012541A Expired - Fee Related KR101832041B1 (ko) 2012-10-18 2013-10-16 국소 스테로이드 조성물 및 방법

Country Status (19)

Country Link
US (3) US8962028B2 (https=)
EP (1) EP2919753A1 (https=)
JP (1) JP6385938B2 (https=)
KR (1) KR101832041B1 (https=)
CN (1) CN104884043B (https=)
AP (1) AP2015008420A0 (https=)
AU (1) AU2013331271B2 (https=)
BR (1) BR112015008951A2 (https=)
CA (1) CA2888853C (https=)
EA (1) EA029494B1 (https=)
IN (1) IN2015DN04160A (https=)
MX (1) MX371362B (https=)
MY (1) MY179354A (https=)
NZ (1) NZ706918A (https=)
PH (1) PH12015500859B1 (https=)
SG (1) SG11201502931YA (https=)
UA (1) UA115073C2 (https=)
WO (1) WO2014062817A1 (https=)
ZA (1) ZA201502692B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534382B2 (en) 2017-06-19 2022-12-27 Novan, Inc. Topical compositions and methods of using the same
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
EP3937905A4 (en) 2019-03-14 2022-12-28 Crescita Therapeutics Inc. RINSING COMPOSITIONS AND THEIR USES FOR THE ADMINISTRATION OF ACTIVE AGENTS
CN109833291B (zh) * 2019-04-03 2022-08-26 普霖贝利生物医药研发(上海)有限公司 一种稳定的丙酸氯倍他索软膏及其制备方法
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
EP4586999A1 (en) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055445A2 (en) 2001-12-21 2003-07-10 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteriod delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
DE3225848A1 (de) * 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
CA2143515A1 (en) 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
US6647058B1 (en) 1997-06-23 2003-11-11 Paradyne Corporation Performance customization system and process for optimizing XDSL performance
US6171985B1 (en) 1997-12-01 2001-01-09 3M Innovative Properties Company Low trauma adhesive article
US6673374B2 (en) 1998-07-31 2004-01-06 Howard Murad Pharmaceutical compositions and methods for managing skin conditions
US6315980B1 (en) 1998-09-25 2001-11-13 Shiseido Company, Ltd. Skin barrier function recovery and promotion composition and evaluation method thereof
WO2000040250A1 (fr) * 1999-01-06 2000-07-13 Taisho Pharmaceutical Co.,Ltd. Lotion a base d'amelometasone
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6790203B2 (en) 2000-12-20 2004-09-14 Sca Hygiene Products Ab Absorbent product comprising leakage barriers
US6830758B2 (en) 2001-04-02 2004-12-14 Lectec Corporation Psoriasis patch
US6781027B2 (en) 2001-12-14 2004-08-24 Kimberly-Clark Worldwide, Inc. Mixed denier fluid management layers
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7208485B2 (en) 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
CN1942178A (zh) 2004-02-19 2007-04-04 奥克塞尔公司 用于治疗皮肤疾病的局部制剂
US20070189980A1 (en) 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196457A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
WO2006110534A2 (en) * 2005-04-07 2006-10-19 Taro Pharmaceuticals U.S.A., Inc. A process for preparing a crystalline form of halobetasol propionate
MX2009011493A (es) 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
RU2470645C2 (ru) * 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
CH701253A1 (de) 2009-06-12 2010-12-15 Mibelle Ag Verwendung eines Extraktes aus Schneealgen in kosmetischen oder dermatologischen Formulierungen.
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055445A2 (en) 2001-12-21 2003-07-10 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteriod delivery

Also Published As

Publication number Publication date
CA2888853C (en) 2019-02-12
BR112015008951A2 (pt) 2017-07-04
CA2888853A1 (en) 2014-04-24
AP2015008420A0 (en) 2015-05-31
US8962028B2 (en) 2015-02-24
MX371362B (es) 2020-01-27
CN104884043B (zh) 2018-12-11
US20140112991A1 (en) 2014-04-24
EA201590730A1 (ru) 2015-08-31
PH12015500859A1 (en) 2015-06-22
UA115073C2 (uk) 2017-09-11
MX2015004863A (es) 2016-02-05
MY179354A (en) 2020-11-04
NZ706918A (en) 2019-01-25
WO2014062817A1 (en) 2014-04-24
CN104884043A (zh) 2015-09-02
JP6385938B2 (ja) 2018-09-05
SG11201502931YA (en) 2015-05-28
KR20150069005A (ko) 2015-06-22
IN2015DN04160A (https=) 2015-10-16
US20140112959A1 (en) 2014-04-24
AU2013331271B2 (en) 2017-09-28
US20150119827A1 (en) 2015-04-30
JP2015534980A (ja) 2015-12-07
EP2919753A1 (en) 2015-09-23
ZA201502692B (en) 2016-01-27
PH12015500859B1 (en) 2015-06-22
EA029494B1 (ru) 2018-04-30
HK1214154A1 (zh) 2016-07-22
AU2013331271A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
KR101832041B1 (ko) 국소 스테로이드 조성물 및 방법
US20230338275A1 (en) Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
CA3162675C (en) Topical roflumilast formulation having antifungal properties
US20240261308A1 (en) Treatment of skin conditions using high krafft temperature anionic surfactants
HK1214154B (zh) 局部類固醇組合物和方法
US20190282501A1 (en) Hydroalcoholic foam formulations of naftifine
HK40118042A (en) Topical roflumilast formulation having antifungal properties
EP4108234A1 (en) Topical pharmaceutical formulation
HK40099803A (en) Topical roflumilast formulation having antifungal properties
HK40099803B (en) Topical roflumilast formulation having antifungal properties
CN115397398A (zh) 环状酯肽的局部药物制剂
HK40041771A (en) Method and formulation for improving roflumilast skin penetration lag time

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240220

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240220